Totally Implantable Venous Access Devices – 20 Years' Experience of Implantation in Cystic Fibrosis Patients

Abstract

ROYLE DAVIES GANNON TOTALLYI MPLANTABLEV ENOUS ACCESS DEVICES -2 0Y EARS' EXPERIENCE OF IMPLANTATION IN CYSTIC FIBROSIS PATIENTSAnn RC oll Surg Engl 2008; 90:6 79-684

Bloodstream infections in cystic fibrosis: Nine years of experience in both adults and children

“…Since then, there have been several case series reporting their use and associated infection rates [5][6][7]. As in other reports, we found the most common causative organisms of TIVADassociated BSI to be coagulase-negative staphylococci (13 Table 1 Causative organisms of significant BSI and their clinical outcome.…”

Staphylococcus lugdunensis bacteraemia secondary to an infected intracardiac fragment of a vascular access device

“…She also had a TIVAD, a device which is generally associated with low rates of infection and other complications. 6 In our case, however, fragmentation of the TIVAD occurred at some point in time prior to admission. The patient did not clearly describe an event which might have been associated with rupture.…”

Impact of the shape of the implantable ports on their efficiency of flow (injection and flushing)

“…The complications reported in the literature correspond to a wide range of causes. Thus, the positioning of the catheter may prevent thrombotic complications, and the use of an open, venous cut-down technique with fluoroscopic control may allow any immediate intrathoracic complications to be avoided 15,16. Complications associated with the percutaneous puncture technique are also reported 17.…”

“…In spite of the maintenance of these ports, sites of stored deposits remain factors for occlusion and for bacterial or fungal colonization. Determining the best conditions for port maintenance is definitely a key parameter when trying to benchmark the functional performances of ports from different manufacturers 15,16. From a geometrical point of view, the different ports are quite similar, except that their sizes correspond to different therapeutic applications, implantation locations, and ages of patients.…”